Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant

Inclusion Criteria

• •1. Subjects with HCC are eligible for this trial. HCC is defined as having at least one of the following:
• •* Biopsy proven HCC or:
• •* A discrete hepatic tumor(s) as defined by the Barcelona (29) criteria for cirrhotic subjects, ≥2cm with arterial hypervascularity and venous or delayed phase washout on CT or MRI.
• •2. Subjects are liver transplant candidates (actively awaiting organ transplant per transplant services in documentation), or, potential liver transplant candidates (at the discretion of the liver team and/or Principal Investigator) advised by liver transplant services as needing local treatment prior to liver transplant evaluation.
• •3. Subjects must be within UCSF criteria (one solitary tumor smaller than 6.5 cm, or patients having 3 or fewer nodules, with the largest lesion being smaller than 4.5 cm or having a total tumor diameter less than 8.5 cm without vascular invasion) and eligible for potential liver transplant.
• •4. Subjects must be eligible per standard of care for either TACE or SBRT procedures.
• •5. Subjects must have a life expectancy of at least 12 weeks.
• •6. Subjects must be 18 years of age or older. Adult subjects of all ages, both sexes and all races will be included in this study.
• •7. Subjects must sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of record .
• •8. Subjects must have a Child-Turcotte-Pugh (CTP) score ≤8.
• •9. Patients must have adequate organ function within 2 weeks of enrollment.
• •* Bone marrow: Platelets ≥30,000/mm3
• •* Renal: BUN ≤40 mg/dl; creatinine ≤2.0 mg/dl
• •* Hepatic: INR ≤ 1.5 or correctable by Vitamin K, unless anti-coagulated for another medical reason
• •* Bilirubin \< 3.0 mg/dl (in the absence of obstruction or pre-existing disease of the biliary tract, e.g. primary sclerosing cholangitis).
• •10. Patients uninvolved liver volume will be estimated and must be \> 700ml.
• •11. Patients must have a Zubrod performance status of ≤2.